-- Caplin Steriles, a subsidiary of Caplin Point Laboratories (NSE:CAPLIPOINT, BOM:524742), has received final approval from the U.S. Food and Drug Administration (FDA) for its calcium gluconate injection, according to a Tuesday filing to the Indian stock exchanges.
The drug is a generic therapeutic equivalent version of Fresenius Kabi's reference-listed drug.
Calcium gluconate injection is indicated for the treatment of acute symptomatic hypocalcemia in pediatric and adult patients.
The company's shares were up nearly 2% in recent trade.